Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies. Like many solid tumors, the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), is shielded by the desmoplastic matrix-a dense barrier … Read more
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient’s T cells to target specific antigens on leukemia cells, with the goal of identifying and eliminating them. However, clinical data show that more than 50% … Read more
Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors – a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made this concept a reality, crafting what they have named the “EchoBack CAR T-cell,” which could soon be a game changer in the field … Read more
Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become an essential part of the treatment of patients whose lymphoma or multiple myeloma has relapsed. This involves genetically modifying the patient’s own T lymphocytes (T cells) … Read more
New research shows that GD2 CAR-T cell therapy offers a potential cure for neuroblastoma, with some patients achieving long-term remission for over a decade—marking a major milestone in solid tumor treatment. Study: Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Image Credit: ART-ur / Shutterstock.com In a recent study published in Nature Medicine, … Read more